UnicoCell Biomed Co., Ltd. (TPE:6794)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
81.20
+0.20 (0.25%)
Apr 17, 2026, 1:30 PM CST
Market Cap5.17B +25.3%
Revenue (ttm)30.10M -5.6%
Net Income-114.84M
EPS-1.89
Shares Out63.64M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume23,000
Average Volume33,681
Open82.50
Previous Close81.00
Day's Range79.10 - 82.50
52-Week Range60.80 - 96.00
Beta-0.22
RSI47.02
Earnings DateMay 11, 2026

About UnicoCell Biomed

UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; UnicoVial, a cryogenic vial for the storage of cell products and biological samples under ultra-low temperature; and laboratory testing services, which include sterility, endotoxin, mycoplasma, and cell coun... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6794
Full Company Profile

Financial Performance

In 2025, UnicoCell Biomed's revenue was 30.10 million, a decrease of -5.58% compared to the previous year's 31.88 million. Losses were -114.84 million, 23.4% more than in 2024.

Financial Statements